SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company - STAA

NEW YORK, July 1, 2014 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA).  Investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 237.

The investigation concerns whether STAAR and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On July 1, 2014, the U.S. Food and Drug Administration (FDA) released a copy of a warning letter that it issued STAAR on May 21, 2014 indicating that the Company's Monrovia, California facility lacks adequate procedures for documenting design of implantable lenses for the eye.  The FDA also cited failures in handling complaints, sterility testing, and keeping required records.  The FDA cited findings from inspections in February-March 2014. 

On this announcement, shares of STAAR fell $3.78, or more than 22.49%, on intraday trading to a price of $13.02 on July 1, 2014.

The Pomerantz Firm, with offices in New York, Chicago, San Diego and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]

SOURCE Pomerantz LLP